| Drug General Information |
| Drug ID |
D06CVO
|
| Former ID |
DCL000913
|
| Drug Name |
OrM3
|
| Indication |
Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47]
|
Phase 2b |
[1]
|
|---|
| Company |
Merck Research Laboratories
|
| Target and Pathway |
| Target(s) |
Muscarinic acetylcholine receptor M5 |
Target Info |
Antagonist |
[1]
|
|---|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Cholinergic synapse
|
|
Regulation of actin cytoskeleton
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Reactome
|
Muscarinic acetylcholine receptors
|
|
G alpha (q) signalling events
|
|
WikiPathways
|
Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
Regulation of Actin Cytoskeleton
|
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
| References |
| REF 1 | Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. |
|---|
